Breaking Finance News

RBC Capital Markets announced Vertex Pharmaceuticals (NDAQ:VRTX), boosting its stock price target to $175.00 today

In a report released on 9/15/2017 RBC Capital Markets increased the stock price target of Vertex Pharmaceuticals (NDAQ:VRTX) to $175.00 reporting a possible upside of 0.13%.

Just yesterday Vertex Pharmaceuticals (NDAQ:VRTX) traded 1.63% higher at $154.21. Vertex Pharmaceuticals’s 50-day moving average is $154.66 and its 200-day moving average is $126.67. The last stock price is up 23.07% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 944,452 shares of VRTX traded hands, down from an average trading volume of 1,861,950

Recent Performance Chart

Vertex Pharmaceuticals (NDAQ:VRTX)

Vertex Pharmaceuticals has 52 week low of $71.46 and a 52 week high of $167.86 with a PE ratio of 149.75 and has a market capitalization of $0.

In addition to RBC Capital Markets reporting its stock price target, a total of 20 brokerages have issued a ratings update on the company. The average stock price target is $110.30 with 8 brokerages rating the stock a strong buy, 10 brokerages rating the stock a buy, 7 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Vertex Pharmaceuticals (NDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.